| Subject |
Fespixon has passed the preliminary review by the National Healthcare Security Administration of China |
- Date of occurrence of the event: 2024/08/07
- Company name: ONENESS BIOTECH CO., LTD.
- Relationship to the Company (please enter ”head office” or ”subsidiaries”): head office
- Reciprocal shareholding ratios: NA
- Cause of occurrence: According to ”National Reimbursement Drug List 2024” announced by The National Healthcare Security Administration of China, Fespixon has passed the preliminary review to negotiable drug.
- Countermeasures: None
- Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
- (1)In accordance with ”National Reimbursement Drug List (NRDL) 2024 Work Plan”, and the ”National Reimbursement Drug List 2024 Application Guidelines”, the National Healthcare Security Administration of China has completed the preliminary review on the qualification of drugs applied to be included in NRDL list and announced the qualified list of negotiable drugs.
- (2)Passing the preliminary review on negotiable drug qualification does not mean the inclusion in the formulary of National Reimbursement Drug List. Expert review, price negotiation, and subsequent steps will be proceeded according to procedures.
|
